# Gemcitabine as a Single Agent in the Maintenance Chemotherapy of Patients With Metastatic Breast Cancer

> **NCT02188693** · — · UNKNOWN · sponsor: **Xijing Hospital** · enrollment: 267 (estimated)

## Conditions studied

- Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer
- Gemcitabine
- Maintenance Chemotherapy

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02188693
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-07
- **Primary completion:** 2017-07
- **Final completion:** 2017-12
- **Target enrollment:** 267 (ESTIMATED)
- **Last updated:** 2014-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02188693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02188693, "Gemcitabine as a Single Agent in the Maintenance Chemotherapy of Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02188693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*